CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, today announced the addition of Keith T. Flaherty, M.D. to its Board of Directors.
Dr. Flaherty is a Professor of Medicine at Harvard Medical School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital, Director of Clinical Research, Massachusetts General Hospital Cancer Center, and Editor-in-Chief of Clinical Cancer Research. He co-founded and served on the Board of Directors of Loxo Oncology, Inc. until its acquisition by Eli Lilly and Company, and he currently serves on the Board of Directors of Clovis Oncology, Inc. (NASDAQ: CLVS). Dr. Flaherty has a Bachelor of Science from Yale University and a medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.
“We welcome Dr. Flaherty to our Board of Directors and are looking forward to his guidance during the exciting times ahead. Keith’s experiences both as a clinical researcher developing innovative oncology products and as a Board member of development-stage oncology companies will be tremendously helpful as we continue to advance Checkmate’s mission to provide transformative new treatment options for oncology patients,” commented Barry Labinger, President and CEO of Checkmate Pharmaceuticals.
“I am excited to join the Checkmate Board at a critical time, as the company advances toward definitive trials to confirm the benefit of CMP-001, having established proof-of-concept that the agent can overcome resistance to PD-1 antibody therapy in melanoma,” commented Dr. Flaherty. “I believe CMP-001 offers promise to enhance immunotherapy for patients with a variety of types of cancer.”
Checkmate Pharmaceuticals is a clinical stage company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate’s lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to PD-1 therapy in some patients.
Checkmate is a privately held company headquartered in Cambridge, MA.
Information regarding Checkmate is available at www.checkmatepharma.com.